Genocea Biosciences Inc (GNCAQ)

[micromillionaire]

Analyzing the Insider Data for Genocea Biosciences, Inc. (GNCA)


By Chelsea Moreno -
October 3, 2017

Recent trading patterns in the stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) have investors on high alert. Analysts often look at historical trading patterns to predict a stock’s future performance. In the case of GNCA, the data might be telling investors a thing or two about where the stock is headed. In the most recent quarter, institutional ownership increased by a net of 1.55 million shares, or 9.15%. This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for GNCA overall. 40 holders increased their positions, 16 decreased their positions, and 14 holders held their positions.

Among institutions that increased their positions, 22 were new positions. Among holders that decreased their positions, 10 sold out of the stock Genocea Biosciences, Inc.. Insider ownership during the latest quarter decreased by a net of 45000 shares, indicating that GNCA’s key executives are feeling more bearish about the stock than they did three months ago. 0 of the trades during the past quarter were buys, and 1 or 100% were sells. Insider ownership during the last year has increased by a net of 47166 shares. 70% of insider trades in the last 12 months were buys, and 30% were sells.

Over the past year, the price of Genocea Biosciences, Inc. (GNCA) has decreased -71.15% while the S&P 500 has increased 17.03%. During the past 20 days, GNCA has decreased -70.02% while the broad market has increased 1.51%. GNCA ‘s 20-day moving average currently sits above its 100-day moving average. This is a bullish signal that suggests the stock price might continue to rise. GNCA’s average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of GNCA’s future price movements.

Genocea Biosciences, Inc. (NASDAQ:GNCA) has a 20-day RSI of 23.04%. According to this momentum indicator, a reading below 30 suggests the stock is becoming oversold and that the recent downtrend may be about to reverse. The MACD tells a different story. GNCA’s 9-day MACD currently sits above the 20-day MACD, indicating that GNCA’s downside momentum has increased during the last three weeks. This suggests that the trend will likely continue. GNCA’s average trading volatility during the past few weeks is 114.8% higher than the average volatility over the past 100 days. This means that the stock’s daily price swings have been more extreme in recent times compared to the past.

Analysts expect Genocea Biosciences, Inc. (GNCA) to generate earnings per share of $1.90 in 2017. This works out to an increase of 8.57% compared to last year’s earnings. For comparison’s sake, analysts expect the S&P 500 to grow earnings by an average of 12% in 2017. The average investment rating for GNCA on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 4.00 or a Moderate Buy. Three months ago, analysts assigned GNCA a 4.50 rating, which implies that analysts have become more pessimistic about the outlook for the stock over the next year.

https://www.nystocknews.com/2017/10/03/analyzing-the-insider-data-for-genocea-biosciences-inc-gnca-2/